Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BTAI 
BioXcel Therapeutics Inc (BTAI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: BTAI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $19.8
1 Year Target Price $19.8
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -92.4% | Avg. Invested days 16 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 47.87M USD | Price to earnings Ratio - | 1Y Target Price 19.8 |
Price to earnings Ratio - | 1Y Target Price 19.8 | ||
Volume (30-day avg) 3 | Beta 0.21 | 52 Weeks Range 1.17 - 13.28 | Updated Date 09/16/2025 |
52 Weeks Range 1.17 - 13.28 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.9 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -13210% |
Management Effectiveness
Return on Assets (TTM) -68.72% | Return on Equity (TTM) -1766.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 139373280 | Price to Sales(TTM) 55.15 |
Enterprise Value 139373280 | Price to Sales(TTM) 55.15 | ||
Enterprise Value to Revenue 163.89 | Enterprise Value to EBITDA -0.75 | Shares Outstanding 16009100 | Shares Floating 14009846 |
Shares Outstanding 16009100 | Shares Floating 14009846 | ||
Percent Insiders 3.8 | Percent Institutions 6.23 |
Upturn AI SWOT
BioXcel Therapeutics Inc
Company Overview
History and Background
BioXcel Therapeutics Inc. was founded in 2010. Initially focused on drug repurposing using artificial intelligence, it has evolved into a biopharmaceutical company developing treatments for neuroscience and immuno-oncology disorders.
Core Business Areas
- Neuroscience: Development and commercialization of therapies for acute agitation associated with schizophrenia or bipolar I or II disorder, and other neurological conditions.
- Immuno-oncology: Research and development of therapies for cancer through modulation of the immune system, although this area is currently less emphasized.
Leadership and Structure
The company is led by a management team with experience in pharmaceutical development and commercialization. The organizational structure includes departments for research and development, clinical operations, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- BXCL501 (DEXMEDETOMIDINE): A sublingual film formulation of dexmedetomidine, marketed as Igalmi, approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. While approved, uptake has been slower than expected, impacting revenue. The competitors are antipsychotics (oral and injectable) and benzodiazepines, which are mainstays of treatment for acute agitation. Exact market share data is unavailable due to the novel nature of the product and limited commercial history, although BXCL501 represents a relatively small portion of the overall market for agitation treatment.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with significant research and development costs. The neuroscience market is growing due to increasing prevalence of mental health disorders and the development of new treatments.
Positioning
BioXcel Therapeutics is positioned as an innovator in the neuroscience space with its AI-driven drug development approach and novel sublingual formulation of dexmedetomidine. Its competitive advantage lies in its potentially faster onset of action and non-invasive administration compared to traditional treatments.
Total Addressable Market (TAM)
The market for acute agitation treatment is estimated to be substantial, potentially exceeding $1 billion annually. BioXcel is positioned to capture a portion of this TAM with Igalmi, though its actual market penetration remains to be seen.
Upturn SWOT Analysis
Strengths
- Novel sublingual formulation of dexmedetomidine (Igalmi)
- AI-driven drug development platform
- Focus on unmet needs in neuroscience
- FDA approval for Igalmi
Weaknesses
- Limited commercial history
- Dependence on a single approved product (Igalmi)
- High cash burn rate
- Uncertainty about market adoption of Igalmi
- Limited Sales
Opportunities
- Expansion of Igalmi's label to other indications (e.g., agitation in dementia)
- Development of new products through its AI platform
- Partnerships with larger pharmaceutical companies
- Further Clinical trials to validate drug effectiveness.
Threats
- Competition from existing treatments (antipsychotics, benzodiazepines)
- Regulatory risks
- Reimbursement challenges
- Potential safety concerns
- Negative clinical trial results
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- OTSK
Competitive Landscape
BioXcel Therapeutics faces competition from established pharmaceutical companies with broader product portfolios and greater financial resources. Its competitive advantage lies in its novel approach to drug development and its focus on specific unmet needs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by research and development milestones and regulatory approvals.
Future Projections: Future growth is dependent on the commercial success of Igalmi and the development of new products. Analyst estimates vary widely due to uncertainty regarding market adoption.
Recent Initiatives: Recent initiatives include expanding the sales force for Igalmi and conducting clinical trials to evaluate its efficacy in additional indications.
Summary
BioXcel Therapeutics is a biopharmaceutical company focused on neuroscience and utilizing AI for drug development. Their primary asset is Igalmi, which is approved for acute agitation. The company faces challenges related to commercialization and competition. Future success hinges on Igalmi's market adoption and pipeline development, along with strategic partnerships, and prudent management of cash resources.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise. Financial projections are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioXcel Therapeutics Inc
Exchange NASDAQ | Headquaters New Haven, CT, United States | ||
IPO Launch date 2018-03-08 | Founder, CEO, President, & Director Dr. Vimal D. Mehta Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 37 | |
Full time employees 37 | |||
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.